



Continuing education for life

Name of Discloser:

- Instructor
 Planner/Manager
 Other

SynAptiv has a policy to ensure balance, independence, objectivity, and scientific rigor in all our continuing education (CE) activities. We must disclose to the audience any real or apparent conflicts of interest (COI) with commercial interests whose products or services may be mentioned in the activity. The Accreditation Council for Continuing Medical Education (ACCME) and California Board of Registered Nursing (CBRN) define a *commercial interest* as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

A COI exists when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of continuing education about the product or services of that commercial interest. We are responsible for collecting information from instructors, planners and managers regarding CE content and resolving those conflicts prior to the commencement of the CE activity. The intent of the COI resolution process is to assure that provider, faculty and planner financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of CE activities for the profession. Any financial relationship with a commercial interest in the last 12 months is considered a conflict of interest. All the recommendations involving clinical medicine in a CE activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.

List the names of proprietary entities producing, marketing, re-selling or distributing health care goods or services, consumed by, or used on, patients with which you or your spouse/partner have, or have had, a relevant financial relationship within the past 12 months. For this purpose we consider the relevant financial relationships of your spouse or partner that you are aware of to be yours. Please indicate spouse or partner relationships in parentheses.

- Grants/Research Support _____
- Consulting Fees (e.g., Ad boards) _____
- Speakers' Bureau _____
- Ownership Interest/Shareholder _____
- Salary _____
- Royalty/Patent Holder _____
- Other _____

Neither I, nor my spouse/partner have had a conflict of interest (COI) with commercial interests whose products or services may be mentioned in the activity within the past 12 months.

For Faculty and Content Reviewers to Complete:

If you reported relationships above, will the relationships impact your ability to present an unbiased presentation? Yes No

- I agree to disclose any unlabeled/unapproved uses of drugs or products referenced in my presentation/materials.
- The content/presentation with which I am involved will promote improvements in healthcare and will not promote a specific proprietary business interest of a commercial interest. My content/presentation will be fair-balanced, evidence-based and unbiased.
- I have not and will not accept any honoraria, additional payments, or reimbursements specific to this activity from any commercial interest.
- If applicable, I understand that to resolve any COI, SynAptiv will review my content/presentation prior to the activity and I will make changes or provide content and resources as required.
- If I am providing recommendations involving clinical medicine, they will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in support of justification of patient care recommendations will conform to the generally accepted standards of experimental design, data collection and analysis.
- If I am discussing specific healthcare products or services, I will use generic names to the extent possible. If I need to use trade names, I will use trade names from several companies when available, and not just trade names from any single company.
- If I have been trained or utilized by a commercial interest or its agent as a speaker (e.g., speakers' bureau), the promotional aspects of that presentation will not be included in any way in this activity.
- If I am presenting research funded by a commercial interest, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interests of the commercial interest.

I have carefully read, considered and agree to each item in this form, and have completed it to the best of my ability. PLEASE ATTACH BIO or CV WITH THIS FORM.

Signature of reporting individual

Date

--	--

(Print Signature Acceptable)

Please return this form to YourCESource via email to cmattingly@yourcesource.org.

Faculty Author and Presenter Guidelines

Please keep the following guidelines in mind when preparing CME presentations:

1. Content should cover and teach to the learning objectives.
2. Content must be scientifically rigorous, present a fair-balanced discussion of all therapeutic options and products, be evidence based, and unbiased.
3. As much as possible, the content should present generic names of products. If trade names must be used, the names of multiple products should be used for balance.
4. Content must be free from commercial bias, it should not advance the proprietary interests of any commercial company.
5. Any unlabeled/unapproved uses of drugs or products discussed in the content must be disclosed to the audience in either the content or verbally at the time of presentation.
6. Any training or utilization by a commercial interest (eg. speakers' bureau) will not in any way include the promotional aspects in the content.
7. Slides or handout materials should not contain any commercial graphic, logo, or product message.
8. All published data, reference studies and articles cited in the content must be properly referenced on slides and handout materials.
9. Content that presents research funded by a commercial interest must only present information that is based on generally accepted scientific principles and methods, and will not promote the commercial interests of the company.
10. Any content presented by an employee of a commercial interest must not include patient care recommendations; must only be on the level of biology, physiology or physics, and far from a discussion of products that are prescribed to patients; must be about the discovery process itself and not about treatment and diagnostics; must only cover research results so early in the discovery process that there is no product yet developed; and must target learners who are scientists also participating in the discovery process.
11. If providing recommendations involving clinical medicine, all recommendations should be based on evidence that is accepted within the professions of medicine as adequate justification for their indications and contraindications in the care of patients.
12. All scientific research referred to, reported or used in support of justification of patient care recommendations should conform to the generally accepted standards of experimental design, data collection and analysis.

Content Standards

The following standards for CME content have been established by the ACCME, AMA and FDA:

1. CME activities are conducted for the education of the audience and, by extension, the benefit of their patients; they must not be designed to promote commercial interests or products.
2. CME activities must be objective and balanced, including presentation of legitimate differences and contrasting views.
3. CME content will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in support of justification of patient care recommendations will conform to the generally accepted standards of experimental design, data collection and analysis.
4. Use of generic names when referring to drugs is strongly encouraged. If trade names are used, those of several companies must be included.
5. Discussion of off-label and investigational usage of products is permissible but must be disclosed as such.
6. The educational content must address the learning objectives for the activity.